10.6
Dissoluzione del farmaco: requisiti e confronto dei profili
I criteri di accettazione per i dati del profilo di dissoluzione sono ancorati ai valori Q, che rappresentano la percentuale di principio attivo disci…
I dati del profilo di dissoluzione sono accettati in base ai valori Q o alla percentuale di farmaco disciolto entro un determinato tempo.
Il test di dissoluzione viene eseguito in tre fasi.
Un farmaco supera il test di fase 1 se tutte e sei le unità di dosaggio sono ≥ Q + 5%; in caso contrario, si passa alla seconda fase.
Qui, la media di dodici unità deve essere ≥ Q e nessuna unità dovrebbe essere < Q - 15%; in caso contrario, si procede alla fase finale.
La fase finale richiede una media di ventiquattro unità da ≥ Q, con non più di 2 unità < Q - 15% e nessuna < Q - 25%.
Inoltre, i confronti dei profili di dissoluzione aiutano a sviluppare prodotti farmaceutici bioequivalenti e a dimostrare l'equivalenza dopo le modifiche alla formulazione.
Implica il calcolo del fattore di differenza, f1, e del fattore di somiglianza, f2. Due profili di dissoluzione sono identici se f1 è 0 e f2 è 100.
View the full transcript and gain access to JoVE Core videos
Q1: What is a Q value in drug dissolution testing?
A Q value represents the percentage of drug dissolved within a specified time period and serves as the acceptance criterion for dissolution profile data. Dissolution testing evaluates whether drug dosage units meet or exceed this Q value threshold across three sequential stages, ensuring consistent drug release and bioavailability.
Q2: How does the three-stage dissolution testing process work?
Stage 1 tests six units; all must be ≥ Q + 5% to pass. Stage 2 tests twelve units; their average must be ≥ Q with none < Q - 15%. Stage 3 tests twenty-four units; their average must meet stage 2 criteria with no more than 2 units < Q - 15% and none < Q - 25%. This progressive approach ensures rigorous quality assessment.
Q3: What happens if a drug fails stage 1 dissolution testing?
If any of the six dosage units in stage 1 fall below Q + 5%, the drug proceeds to stage 2 testing, which involves a larger sample of twelve units. This tiered system allows drugs that don't meet the initial strict criteria a second opportunity to demonstrate acceptable dissolution performance.
Q4: What are the difference factor and similarity factor in dissolution profiles?
The difference factor (f1) and similarity factor (f2) quantify differences between two dissolution profiles. Two profiles are identical when f1 equals 0 and f2 equals 100. These factors help demonstrate bioequivalence and assess whether formulation changes maintain equivalent drug release, supporting clinically relevant drug product specifications methods establishment.
Q5: Why are dissolution profile comparisons important in drug development?
Dissolution profile comparisons help develop bioequivalent drug products and demonstrate equivalence after formulation changes. By comparing f1 and f2 values between test and reference products, manufacturers ensure that modifications maintain consistent drug performance and therapeutic effectiveness throughout the product lifecycle.
Q6: What conditions must be met when comparing dissolution profiles between products?
Profile comparisons require a minimum of three dissolution time points measured on twelve drug products for both test and reference cases. At most one mean value exceeding 85% dissolved is allowable per product, and standard deviation of any product should not exceed 10% from the second to final time point.
Q7: How does dissolution testing support bioequivalent drug product development?
Dissolution testing establishes baseline drug release profiles and enables comparison between formulations using f1 and f2 factors. This in vitro drug release testing overview development and validation ensures that generic or reformulated products release drug at rates equivalent to reference products, confirming therapeutic bioequivalence.